Marloes A G Elferink
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marloes A G Elferink has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Geraldine R. Vink
Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
32 shared publications - Johannes H. W. de Wilt
Department of Surgery, Radboud University Medical Centre, Nijmegen, The Netherlands
32 shared publications - Hidde Swartjes
Department of Surgery, Radboud University Medical Center, Nijmegen, The Netherlands
31 shared publications - Marjolein J. E. Greuter
Department of Epidemiology and Data Science, Amsterdam Public Health, Amsterdam UMC, Vrije Universiteit Amsterdam, C-371, Van der Boechorststraat 7, 1081 BT, Amsterdam, The Netherlands.
31 shared publications - Rik van Eekelen
Centre for Reproductive Medicine, Amsterdam UMC, Amsterdam, the Netherlands
31 shared publications - Tara C. Boute
Department of Epidemiology and Data Science Amsterdam Public Health Research Institute, Amsterdam UMC, Location Vrije Universiteit Amsterdam the Netherlands
31 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Wiley in Histopathology
Tumour deposits are associated with increased metastatic risk in colorectal cancer: a population‐based analysis of metastatic patterns and burden
Aims: Lymph node metastases (LNM) are traditionally regarded as the principal gateway for distant metastases in colorectal cancer (CRC), forming the foundation of TNM staging. Tumour deposits (TD) have emerged as a strong prognostic factor and potential alternative gateway for CRC spread. This study aimed to assess whether TD were associated with the risk of distant metastases and to characterize metastatic patterns and burden. Methods and results: A retrospective, population‐based study included 3505 CRC patients without distant metastases at diagnosis, using data from the Netherlands Cancer Registry for the first half of 2015. Cox regression was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for metastatic risk. Metastatic patterns were summarized descriptively using pattern‐to‐patient ratios. Metastatic burden was categorized by the number of involved sites (1, 2, 3 or ≥4) and evaluated using the linear‐by‐linear association test. Of the 3505 patients, 2268 were N0, 934 were LNM+ and 303 were LNM + TD+. TD were independently associated with an increased risk of distant metastases (HR = 1.34, 95% CI: 1.03–1.74). Among patients who developed distant metastases, pattern‐to‐patient ratios were 0.30, 0.34 and 0.39 in the N0, LNM+ and LNM + TD+ groups, respectively, but were not formally compared because of their dependence on sample size. The distribution of metastatic burden differed across the three groups ( P for trend = 0.017). The proportion with ≥4 involved sites was descriptively highest in the LNM + TD+ group (18.0% vs. 11.0% in LNM+ and 9.2% in N0). Conclusions: TD are independently associated with an increased risk of distant metastases in CRC. This finding supports consideration of TD in future risk stratification strategies and warrant further investigation into whether TD mark a distinct metastatic phenotype rather than merely reflecting locoregional disease progression.
- 30 September 2026
- Published by Wiley in Histopathology
Open AccessTumour deposits are associated with increased metastatic risk in colorectal cancer: a population‐based analysis of metastatic patterns and burden
Aims: Lymph node metastases (LNM) are traditionally regarded as the principal gateway for distant metastases in colorectal cancer (CRC), forming the foundation of TNM staging. Tumour deposits (TD) have emerged as a strong prognostic factor and potential alternative gateway for CRC spread. This study aimed to assess whether TD were associated with the risk of distant metastases and to characterize metastatic patterns and burden. Methods and results: A retrospective, population‐based study included 3505 CRC patients without distant metastases at diagnosis, using data from the Netherlands Cancer Registry for the first half of 2015. Cox regression was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for metastatic risk. Metastatic patterns were summarized descriptively using pattern‐to‐patient ratios. Metastatic burden was categorized by the number of involved sites (1, 2, 3 or ≥4) and evaluated using the linear‐by‐linear association test. Of the 3505 patients, 2268 were N0, 934 were LNM+ and 303 were LNM + TD+. TD were independently associated with an increased risk of distant metastases (HR = 1.34, 95% CI: 1.03–1.74). Among patients who developed distant metastases, pattern‐to‐patient ratios were 0.30, 0.34 and 0.39 in the N0, LNM+ and LNM + TD+ groups, respectively, but were not formally compared because of their dependence on sample size. The distribution of metastatic burden differed across the three groups ( P for trend = 0.017). The proportion with ≥4 involved sites was descriptively highest in the LNM + TD+ group (18.0% vs. 11.0% in LNM+ and 9.2% in N0). Conclusions: TD are independently associated with an increased risk of distant metastases in CRC. This finding supports consideration of TD in future risk stratification strategies and warrant further investigation into whether TD mark a distinct metastatic phenotype rather than merely reflecting locoregional disease progression.
- 5 April 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 240, 116732
Income, treatment patterns and outcome in patients with stage IV colorectal cancer
- 5 April 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 240, 116732
Income, treatment patterns and outcome in patients with stage IV colorectal cancer
- 17 February 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 237, 116588
Safety and feasibility of S-1 after capecitabine-induced toxicity in the adjuvant treatment of colon cancer patients: A population-based real-world study
- 17 February 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 237, 116588
Safety and feasibility of S-1 after capecitabine-induced toxicity in the adjuvant treatment of colon cancer patients: A population-based real-world study
- Open Access
- 21 November 2025
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 10
Recommendations and definitions for time-to-event endpoints using real-world data in oncology
- 21 November 2025
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 10
Open AccessRecommendations and definitions for time-to-event endpoints using real-world data in oncology
- Open Access
- 29 August 2025
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 51 (11) , 110411
Selection for local treatment and outcomes of surgical resection in patients with synchronous colorectal liver metastases: A nationwide population-based study
- 29 August 2025
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 51 (11) , 110411
Open AccessSelection for local treatment and outcomes of surgical resection in patients with synchronous colorectal liver metastases: A nationwide population-based study
- Open Access
- 25 April 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 222, 115469
Trends in resection rates and postoperative mortality for gastrointestinal cancers between 2005 and 2020 in the Netherlands
- 25 April 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 222, 115469
Open AccessTrends in resection rates and postoperative mortality for gastrointestinal cancers between 2005 and 2020 in the Netherlands
- Open Access
- 29 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Cumulative Incidence, Risk Factors, and Overall Survival of Disease Recurrence after Curative Resection of Stage II–III Colorectal Cancer: A Population-based Study
Univariable and multivariable competing risk regression output for the risk of recurrent disease in rectal cancer patients
- 29 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Cumulative Incidence, Risk Factors, and Overall Survival of Disease Recurrence after Curative Resection of Stage II–III Colorectal Cancer: A Population-based Study
Univariable and multivariable competing risk regression output for the risk of recurrent disease in rectal cancer patients
- Open Access
- 29 February 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 3 from Cumulative Incidence, Risk Factors, and Overall Survival of Disease Recurrence after Curative Resection of Stage II–III Colorectal Cancer: A Population-based Study
Forest plot of risk for diagnosis with recurrent disease in patients with primary colon and rectal cancer, based on multivariable competing risk regression models. HR; Hazard ratio. ASA; American Society of Anesthesiologists. R0; resection margin of ≥1 mm. R1; resection margin of 0–1 mm. R2; macroscopically incomplete resection margin. IMVI; intramural vascular invasion. EMVI; extramural vascular invasion.
- 29 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 3 from Cumulative Incidence, Risk Factors, and Overall Survival of Disease Recurrence after Curative Resection of Stage II–III Colorectal Cancer: A Population-based Study
Forest plot of risk for diagnosis with recurrent disease in patients with primary colon and rectal cancer, based on multivariable competing risk regression models. HR; Hazard ratio. ASA; American Society of Anesthesiologists. R0; resection margin of ≥1 mm. R1; resection margin of 0–1 mm. R2; macroscopically incomplete resection margin. IMVI; intramural vascular invasion. EMVI; extramural vascular invasion.
- Open Access
- 29 February 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 1 from Cumulative Incidence, Risk Factors, and Overall Survival of Disease Recurrence after Curative Resection of Stage II–III Colorectal Cancer: A Population-based Study
Cumulative incidence function for diagnosis of recurrent disease in patients with primary colon (A) and rectal cancer (B), stratified for primary disease stage and presented with the corresponding 95% confidence bands.
- 29 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 1 from Cumulative Incidence, Risk Factors, and Overall Survival of Disease Recurrence after Curative Resection of Stage II–III Colorectal Cancer: A Population-based Study
Cumulative incidence function for diagnosis of recurrent disease in patients with primary colon (A) and rectal cancer (B), stratified for primary disease stage and presented with the corresponding 95% confidence bands.